FGF21 and metabolic disease: One gene therapy strategy involves using an AAV-FGF21 vector to enhance the interaction between the fibroblastic growth factor FGF21 and its coreceptor β-klotho, thereby activating the ERK1/2 and MAPK signaling pathways to address metabolic diseases [153,154].